[HTML][HTML] Anticancer drug resistance: An update and perspective
R Nussinov, CJ Tsai, H Jang - Drug Resistance Updates, 2021 - Elsevier
Driver mutations promote initiation and progression of cancer. Pharmacological treatment
can inhibit the action of the mutant protein; however, drug resistance almost invariably …
can inhibit the action of the mutant protein; however, drug resistance almost invariably …
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Normal cells explore multiple states to survive stresses encountered during development
and self-renewal as well as environmental stresses such as starvation, DNA damage, toxins …
and self-renewal as well as environmental stresses such as starvation, DNA damage, toxins …
Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance
It is well established that multifactorial drug resistance hinders successful cancer treatment.
Tumor cell interactions with the tumor microenvironment (TME) are crucial in epithelial …
Tumor cell interactions with the tumor microenvironment (TME) are crucial in epithelial …
Hypoxia as a driver of resistance to immunotherapy
J Kopecka, IC Salaroglio, E Perez-Ruiz… - Drug Resistance …, 2021 - Elsevier
Hypoxia, a hallmark of solid tumors, determines the selection of invasive and aggressive
malignant clones displaying resistance to radiotherapy, conventional chemotherapy or …
malignant clones displaying resistance to radiotherapy, conventional chemotherapy or …
Apoptosis deregulation and the development of cancer multi-drug resistance
Simple Summary Despite recent therapeutic advances against cancer, many patients do not
respond well or respond poorly, to treatment and develop resistance to more than one anti …
respond well or respond poorly, to treatment and develop resistance to more than one anti …
[HTML][HTML] Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects
Abstract P-glycoprotein (P-gp) is a drug efflux transporter that triggers doxorubicin (DOX)
resistance. In this review, we highlight the molecular avenues regulating P-gp, such as Nrf2 …
resistance. In this review, we highlight the molecular avenues regulating P-gp, such as Nrf2 …
3D cell culture models as recapitulators of the tumor microenvironment for the screening of anti-cancer drugs
Simple Summary Three-dimensional (3D) cell culture models have been proposed as
alternatives for initial drug screening to increase drug development efficiency. In addition to …
alternatives for initial drug screening to increase drug development efficiency. In addition to …
Novel nanomedicines to overcome cancer multidrug resistance
Z Su, S Dong, SC Zhao, K Liu, Y Tan, X Jiang… - Drug Resistance …, 2021 - Elsevier
Chemotherapy remains a powerful tool to eliminate malignant cells. However, the efficacy of
chemotherapy is compromised by the frequent emergence of intrinsic and acquired …
chemotherapy is compromised by the frequent emergence of intrinsic and acquired …
Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
Y Yang, S Li, Y Wang, Y Zhao, Q Li - Signal transduction and targeted …, 2022 - nature.com
Protein tyrosine kinases (PTKs) are a class of proteins with tyrosine kinase activity that
phosphorylate tyrosine residues of critical molecules in signaling pathways. Their basal …
phosphorylate tyrosine residues of critical molecules in signaling pathways. Their basal …
Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp)
H Zhang, H Xu, CR Ashby Jr, YG Assaraf… - Medicinal research …, 2021 - Wiley Online Library
Multidrug resistance (MDR) remains one of the major impediments for efficacious cancer
chemotherapy. Increased efflux of multiple chemotherapeutic drugs by transmembrane ATP …
chemotherapy. Increased efflux of multiple chemotherapeutic drugs by transmembrane ATP …